Business
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration
Q4 2022 Preliminary Unaudited Net Revenue of Approximately $43.6 Million, Up 26% from Q4 2021 Full-Year 2022 Preliminary Unaudited Net Revenue of
About this update from Evolus, Inc. Common Stock
[{"type":"text","content":"\n\nQ4 2022 Preliminary Unaudited Net Revenue of Approximately $43.6 Million, Up 26% from Q4 2021\n\n\nFull-Year 2022 Preliminary Unaudited Net Revenue of Approximately $148.6 Million, Up 49% Over 2021\n\n\n2023 Net Revenue Expected to be $180 to $190 Million\n\n\nProjecting Profitability, Positive Non-GAAP Operating Income1 in Q4 2023\n\n\nEstimating Organic Net Revenue to Reach $500 Million by 2028, a 22% CAGR\n\n\n NEWPORT BEACH, Calif.--(BUSINESS WIRE)--\nEvolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced its preliminary, unaudited net revenue as of and for the fourth quarter and full-year ended December 31, 2022. The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company’s 2022 financial results is completed and the company reports its full financial results for the fourth quarter and full-year 2022, which is anticipated to occur in early March 2023.\n\n“We are very pleased to announce record fourth quarter 2022 revenue that demonstrated continued strong customer adoption and further market share gains,” said David Moatazedi, President and Chief Executive Officer. “During the quarter, we continued to add customer accounts and expand our consumer loyalty program, with both metrics reaching all-time highs. This helped drive sales growth well above the projected growth rate of our industry, making Jeuveau® the fastest-growing neurotoxin in the U.S. for the second consecutive year. Our focus on the millennial consumer, the most rapidly-growing neurotoxin user segment, and our unique business model represents a powerful formula that gives us the confidence to project our total net revenue can reach $500 million by 2028, a compound organic growth rate of 22%.”\n\nPreliminary Unaudited 2022 Results and Key Business Highlights\n\n\nTotal net revenues for the fourth quarter of 2022 were approximately $43.6 million, a 26% increase over the fourth quarter of 2021, driven primarily by higher volumes from market share gains, and a modestly higher average selling price.\n\n\nTotal net revenues for the full year 2022 were approximately $148.6 million, a 49% increase over full-year net revenues in 2021 and at the...